EGFR and non-small cell lung carcinoma: More recently, the LAURA trial demonstrated the efficacy of Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), consolidation in EGFR-mutated NSCLC.